Any feedback?
Literature summary for 3.4.14.5 extracted from
- 11 Years of cyanopyrrolidines as DPP-IV inhibitors (2007), Curr. Top. Med. Chem., 7, 579-595.
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | DPP-IV is a target for the treatment of type 2 diabetes. The inhibitors vildagliptin and saxagliptin are well tolerated and reduce blood glucose and HbA1c levels in diabetic patients | Homo sapiens |
Inhibitors
| Inhibitors | Comment | Organism | Structure |
|---|---|---|---|
| saxagliptin | - |
Homo sapiens |  |
| vildagliptin | - |
Homo sapiens | |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | - |
- |
- |
Synonyms
| Synonyms | Comment | Organism |
|---|---|---|
| DPP-IV | - |
Homo sapiens |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
